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RESEARCH ARTICLE
Accelerated Repair of Demyelinated CNS
Lesions in the Absence of Non-muscle
Myosin IIB
Tomasz Rusielewicz,1,2 Jennifer Nam,1 Evangelos Damanakis,1 Gareth R. John,3
Cedric S. Raine,4,5,6 and Carmen V. Melendez-Vasquez1
The oligodendrocyte (OL), the myelinating cell of the central nervous system, undergoes dramatic changes in the organization
of its cytoskeleton as it differentiates from a precursor (oligodendrocyte precursor cells) to a myelin-forming cell. These
changes include an increase in its branching cell processes, a phenomenon necessary for OL to myelinate multiple axon
segments. We have previously shown that levels and activity of non-muscle myosin II (NMII), a regulator of cytoskeletal
contractility, decrease as a function of differentiation and that inhibition of NMII increases branching and myelination of OL in
coculture with neurons. We have also found that mixed glial cell cultures derived from NMIIB knockout mice display an
increase in mature myelin basic protein-expressing OL compared with wild-type cultures. We have now extended our
studies to investigate the role of NMIIB ablation on myelin repair following focal demyelination by lysolecithin. To this end,
we generated an oligodendrocyte-specific inducible knockout model using a Plp-driven promoter in combination with a
temporally activated CRE-ER fusion protein. Our data indicate that conditional ablation of NMII in adult mouse brain,
expedites lesion resolution and remyelination by Plp1 oligodendrocyte-lineage cells when compared with that observed in
control brains. Taken together, these data validate the function of NMII as that of a negative regulator of OL myelination
in vivo and provide a novel target for promoting myelin repair in conditions such as multiple sclerosis.
GLIA 2014;62:580–591
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Introduction
The process of myelination, which provides neuronal axonswith a specialized proteolipid-rich membrane, permits
rapid conduction of action potentials and is orchestrated in
the central nervous system (CNS) by a subset of glial cells
called oligodendrocytes (OL). Although myelin is not neces-
sary for neuronal communication at short distances, it
becomes vital when connecting processes of greater length,
such as those between the two hemispheres of the brain or
the length of the spinal cord. Aside from its electrical insula-
tor properties, myelin also plays a role in axonal maintenance
[reviewed in Nave (2010)]. Loss of myelin in diseases such as
multiple sclerosis (MS) results in conduction failure, and
underlies many of the clinical deficits (weakness, paralysis,
and blindness) associated with this disorder.
MS is believed to be an autoimmune disorder of the
human CNS, with inflammatory cells invariably present in
demyelinating lesions, but the primary cause of lesion forma-
tion and whether it originates from a problem with myelin
itself or some environmental insult, is not well understood.
Recovery of neural function accompanies remyelination,
which restores nerve conduction and re-establishes the normal
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molecular organization of the myelinated axon (Salzer, 2003).
Remyelination is mediated by several sources of oligodendro-
cyte precursor cells (OPC), some of which like neural progen-
itors cells migrate from the sub-ventricular zone, while others
such as NG21 progenitors are found throughout the adult
CNS (Levine et al., 2001; Nielsen et al., 2006). Although
remyelination in MS is initially associated with OPC prolifer-
ation (Raine et al., 1981), over time as lesions expand and
become chronic, this repair process becomes less efficient, as
there is little that can be done to limit the progressive burden
on the reservoir of OPC resulting from recurrent demyelin-
ation (Franklin, 2002).
The cellular mechanism whereby OL extend multiple
cell processes that wrap around CNS axons is still poorly
defined but involves active remodeling of the cytoskeleton.
These morphological changes have been linked to differentia-
tion and myelin formation both in vivo and in vitro (Bauer
et al., 2009; Kim et al., 2006; Sloane and Vartanian, 2007).
We have previously shown that levels of non-muscle myosin
II (NMII), which generates the force for cytoskeletal contrac-
tility, decrease as a function of OL differentiation and that
inhibition of myosin activity increases branching and myeli-
nation by OL in co-culture with neurons (Wang et al.,
2008). Our group has also demonstrated accelerated matura-
tion of OL purified from NMIIB null mice (Wang et al.,
2012).
As the process of remyelination recapitulates events tak-
ing place during normal OL development (Fancy et al., 2011;
Moll et al., 2013), we have tested the hypothesis that condi-
tional ablation of NMIIB in adult brain may promote myelin
repair via acceleration of OL differentiation. Using the lyso-
lecithin model of demyelination, we show here that targeted
deletion of NMIIB from OL expressing proteolipid protein
(Plp) accelerates lesion resolution and increases the number of
mature CC11 OL found inside the remyelinating lesion.
Collectively, our results provide a novel strategy to enhanced
myelin repair by promoting OL maturation.
Materials and Methods
Mice
NMIIB fl/fl mice (Ma et al., 2009) were provided by Mary Anne
Conti and Robert S. Adelstein (Laboratory of Molecular Cardiology,
NHLBI) and are available from MMRRC (Stock #016981-UNC).
PlpCre/ESR1 mice (Doerflinger et al., 2003) were purchased from
the Jackson Laboratory (Stock # 005975). Gt(ROSA)26Sort-
m4(ACTB-tdTomato,-EGFP)Luo/J (Rosa26-mT/mG) mice (Muzum-
dar et al., 2007) (Jackson Laboratory, Stock # 007576) were
provided by Paul Feinstein (Hunter College, CUNY). PlpCre/ESR1
hemizygous mice were crossed with Rosa26-mT/mG heterozygotes
to check for recombination efficiency. PlpCre/ESR1 males were
crossed with NMIIB fl/fl females and the F1 PlpCre/ESR1:NMIIB fl/1
males were then backcrossed to NMIIB fl/fl females to generate
PlpCre/ESR1:NMIIB fl/fl (cKO) and NonCre:NMIIB fl/fl (Control)
mice for remyelination analysis. PlpCre/ESR1:NMIIB fl/1 animals were
also crossed to the offspring (F1) from a Rosa26-mT/mG x NMIIB fl/fl
cross to generate PlpCre/ESR1:Rosa26-mT/mG:NMIIB fl/fl (mT/mG;
cKO) and PlpCre/ESR1:Rosa26-mT/mG:NMIIB 1/1 (mT/mG;
Control). All procedures were performed in accordance with the
National Institutes of Health guidelines and were approved by
Hunter College Institutional Animal Care and Use Committee.
Tamoxifen Recombination and Lysolecithin
Injections
Eight-week-old mice were injected intraperitoneally with 49 mg/kg
tamoxifen for 5 consecutive days. For demyelination, 12-week-old
mice injected unilaterally into the corpus callosum (5.5 mm anterior
to lambda, 1 mm lateral to bregma, 2 mm deep) with 1.5 mL of a
solution of 1% lysolecithin in PBS (Nait-Oumesmar et al., 1999).
Animals were sacrificed 7, 14, or 28 days later. These time points
correspond to well-characterized phases of active demyelination, pro-
liferation and remyelination of lysolecythin-induced lesions (Zhang
et al., 2009).
Immunocytochemistry
Mice were euthanized and perfused transcardially with 4% parafor-
maldehyde. Brain-frozen sections (30 mm) were collected over a
1mm distance centered on the needle track. Sections were processed
for immunofluorescence as described (Wang et al., 2008) and
imaged using a Zeiss LSM 510 confocal microscope.
Image Analysis
Image analysis was performed using ImageJ 1.46m and Adobe Pho-
toshop CS5. Adjustment of image brightness or contrast was per-
formed in some cases but without misrepresenting data. Lesion area
was measured using the freehand selection tool inside FluoroMyelin
negative areas. Lesion size and volume calculations were based on
the number of sections collected for each lesion multiplied by their
thickness and their average lesion area. Fluorescence intensity for
specific antibodies within the lesion area was measured using the
mean gray value. All measurements were normalized by the back-
ground mean gray value obtained from a section of normal appear-
ing white matter adjacent to the lesion. When calculating
remyelination by EGFP1 oligodendrocytes at 28 dpi, the particle
analysis tool was used to measure the total cell area (including cell
body and processes) within the lesion shadow (EGFP2, MBP1).
This value was then divided by the total shadow area, to obtain the
percentage covered by EGFP1 oligodendrocytes. Statistical tests were
performed using Graph Pad Prism software.
Histopathology
Mice were perfused with 2.5% gluteraldehyde and brain tissue was
trimmed and postfixed in 1.5% osmium tetroxide followed by dehy-
dration in 30–100% ethanol and embedding in Epon. Semithin sec-
tions (1 mm) were stained with toluidine blue and imaged using a
Zeiss Axioplan microscope. For EM sections were stained with uranyl
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acetate and lead citrate and imaged using TEM (JEOL JEM-100C/
HS-600SCX). g-Ratios [(axon diameter)/(fiber diameter)] were meas-
ured from electron micrographs of the corpus callosum of 16-week-
old mice using Image J.
Antibodies
NG2 (AB5320), CC1 (OP80), and Olig2 (AB9610) from EMD
Millipore Corporation, Billerica, MA; GFAP (#3670, Cell Signaling
Technology); NF (PCK-593P) and MBP (SMI-94R) from Covance;
and Iba1 (#019-19741, Wako). FITC, Rho, or Cy5-conjugated sec-
ondary antibodies were purchased from Jackson ImmunoResearch
Laboratories. FluoroMyelin (F34651) and Topro 3 (T3604) from
Invitrogen were also used.
Results
Ablation of NMII in Adult Oligodendrocytes Does
Not Affect Myelin Morphology
To explore the functional relevance of NMIIB to myelin
repair in vivo, we generated mice with tamoxifen-inducible
inactivation of NMIIB in glia, by mating PlpCre/ESR1 mice
(Doerflinger et al., 2003) to floxed NMIIB animals (NMIIB
fl/fl) (Ma et al., 2009). PlpCre/ESR1:NMIIB fl/fl (cKO) mice
are viable, phenotypically normal, and born at the expected
Mendelian ratios. PlpCre/ESR1 system has been extensively
used to generate tamoxifen-induced, Cre-mediated recombi-
nation under the control of the myelin proteolipid protein
(Plp1) promoter (Doerflinger et al., 2003; Forrest et al.,
2009; Pillai et al., 2009); and previous studies have shown
that upon treatment with tamoxifen, efficient recombination
occurs in developing OPC and mature myelinating OL
throughout the adult CNS as well as developing and mature
Schwann cells in the peripheral nerve (Doerflinger et al.,
2003; Leone et al., 2003).
We performed our own assessment of PlpCre/ESR1
mediated-recombination 4 weeks after tamoxifen treatment of
8-week-old mice, using the reporter line Rosa26-mT/mG
(Muzumdar et al., 2007) and confirmed extensive and effi-
cient recombination in myelinating OL (MBP1, CC11)
throughout corpus callosum, cortex, striatum, spinal cord,
and optic nerve (Fig. 1) as well as NG2- (Fig. 1D) cell with a
morphology consistent with that of non-myelinating pre-oli-
godendrocytes (Chang et al., 2002). Approximately 87% of
the MBP1 white matter area in the corpus callosum of
12-week-old cKO mice contained EGFP1 cells indicating
extensive recombination. Recombination was also detected in
myelinating Schwann cells in the sciatic nerve (Fig. 1H).
NMIIB is the main myosin II isoform expressed by
oligodendrocytes in vitro (Wang et al., 2012), and although
their expression levels correlate negatively with myelination
(Dugas et al., 2006; Wang et al., 2008), we evaluated whether
conditional ablation of NMIIB in adult OL per se had an effect
on myelin maintenance and/or organization. To this end, we
examined uninjured brain from cKO (PlpCre/ESR1:NMIIB fl/fl)
and control (NonCre:NMIIB fl/fl) mice by light and electron
microscopy and confirmed the presence of normal appearing
white matter in cKO brain (Fig. 2). Detailed morphometric
analysis performed in 16-week-old mice (the end-point of our
remyelination studies) showed no differences in g-ratio, myelin
thickness, and/or periodicity between uninjured control and
cKO brains. These results indicate that NMIIB expression is
not required for myelin maintenance.
Remyelination Is Accelerated in the Absence of
NMII
To test if ablation of NMII in adult brain potentiates CNS
remyelination, we induced focal demyelination in 12-week-old
cKO (PlpCre/ESR1: NMIIB fl/fl), and control (NonCre:NMIIB
fl/fl) mice, via stereotactic injection of lysolecithin into the cor-
pus callosum. Importantly, analysis 14 days after lysolecithin
injection (14 dpi) showed the presence of significantly smaller
demyelinated lesions (FluoroMyelin negative area) in the cor-
pus callosum of cKO mice compared with controls (Fig.
3A,B). Quantitation of total lesion volume (Fig. 3C) showed
that lesions in the cKO were on average 50% smaller than
those found in control animals (47.46 11.2 3 106 mm3 for
cKO vs. 886 40.6 3 106 mm3 for control; mean6 SD;
P5 0.007, t-test).
Despite the presence of a comparable number of Olig21
cells at the lesion site (Fig. 3D) in both control (10.96 1.2 3
104 cells/mm2) and cKO mice (11.46 0.4 3 104 cells/mm2),
we found a significant increase in the number of mature CC11
oligodendrocytes (Fig. 3B,E) present at the lesion at 14 dpi in
cKO mice compared with controls (10.16 3 3 104 cells/mm2
in cKO vs. 6.86 2.2 3 104 cells/mm2 in control; mean6 SD;
P5 0.002, t-test). These data suggest that oligodendrocyte dif-
ferentiation was accelerated in cKO mice, in agreement with
our in vitro data showing increased OL maturation in cultures
derived from NMIIB KO embryonic brains (Wang et al.,
2012).
To rule out that the reduction in lesion size observed in
cKO mice at 14 dpi was due to a difference in the initial
extent of demyelination, we measured the maximal lesion vol-
ume at 7 dpi (Fig. 4A,B), the peak of demyelination in the
lysolecithin model, and found that it was comparable to that
of controls (338.86 227.1 3 106 mm3 for cKO vs.
4616 181.9 3 106 mm3, for controls). Similarly, analysis of
lesion volume at 28 dpi (Fig. 4A,B), the end point of the
experiment, indicated that both cKO and control mice
repaired fully (33.36 12.6 3 106 mm3 for cKO vs.
19.96 11.7 3 106 mm3 for controls).
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Morphological analysis by light and electron microscopy
(Fig. 5) further confirmed our immunofluorescence results,
showing that at 14 dpi, lesions in the cKO brain were smaller
(Fig. 5A), and contained more cells with a round, small, and
dark nucleus characteristic of oligodendrocytes, as well as
many thinly myelinated axons (Fig. 5B,C), a landmark of
remyelination (Fields and Ellisman, 1986). Of note, remyeli-
nated axons were observed as early as 7 dpi in cKO (Fig. 5E),
a very rare event in control animals (Fig. 5D). Of note, no
differences in cell proliferation (Ki67 staining), apoptosis
(Caspase 3 staining), or in the total number of Olig21 at the
lesion site were observed between control and cKO lesions
(Table 1). These data are in agreement with our previous
in vitro work demonstrating that inhibition of NMII does
FIGURE 1: Analysis of tamoxifen-driven PlpCre/ESR1 recombination. Rosa26-mT/mG mice have loxP sites on either side of a membrane-
targeted tdTomato cassette and express strong red fluorescence in all tissues. When bred to PlpCre/ESR1 mice, the resulting offspring
have the mT cassette deleted in the Cre-expressing cells, allowing expression of the membrane-targeted EGFP cassette. NMIIB fl/fl mice
carrying both the PlpCre/ESR1 transgene and the Rosa26-mT/mG allele (Plp-Cre1) or Rosa26-mT/mG allele alone (NonCre) were injected
with tamoxifen for 5 days at 8 weeks of age. The animals were sacrificed at 12 weeks and their tissue was processed for immunofluores-
cence with antibodies to CC1, MBP, NG2, Olig2, and the nuclear stain Topro3. (A, B): Sections of the corpus callosum (CC) show high
EGFP expression in OLs in the white matter tract as well as in the cerebral cortex (CTX) and striatum (St). Scale bars 100 mm. (C–H):
Details of cells expressing EGFP throughout the CNS. In the cortex (C, D) EGFP label colocalizes (shown in white) with mature OL
markers such as MBP (C’), but not with NG2 (D’). Recombination is also observed in myelinating OL in the striatum (E), spinal cord (F)
and optic nerve (G) as well as in myelinating Schwann cells in the sciatic nerve (H).
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not enhance proliferation of progenitors in coculture with
neurons (Wang et al., 2008), and that in the absence of
NMIIB oligodendrocyte differentiation is accelerated as
shown by an increase in the number of MBP1 cells isolated
from the brains of myosin II KO mice (Wang et al., 2012).
Collectively, these results are consistent with the hypothe-
sis that similar to its effects during OL development in vitro,
ablation NMIIB potentiates myelin formation and repair
in vivo.
Axonal Preservation and Recruitment of NG21
Progenitors Are Not Altered by the Absence of
NMIIB
Although primary demyelination is the main effect following
focal injection of lysolecithin into white matter, minimal axo-
nal damage has been reported within lesions (Woodruff and
Franklin, 1999). As remyelination has been associated with
axonal preservation and neuroprotection (Kornek et al., 2000;
Raine and Cross, 1989), we examined the extent of neurofila-
ment staining in both cKO and control lesions to establish if
axon preservation was enhanced in the absence of NMIIB.
We found that neurofilament staining intensity at the center
of the lesion was comparable at 7 (Table 1) and 14 dpi (Fig.
6) for both control and cKO mice. Although staining appears
somewhat reduced in controls compared with cKO at 14 dpi
(Fig. 6A,B) this difference was not statistically significant.
Similarly, the staining for NG21 progenitors, cells that
mediate CNS repair and remyelination (Kucharova et al., 2011;
Watanabe et al., 2002), although slightly increased in cKO mouse
lesions, was not statistically significant compared with controls
(Fig. 6A,B). Collectively, these results suggest that improved
remyelination in cKO mice was not due to better axonal preserva-
tion and/or enhanced recruitment of NG21 progenitors.
Inflammation and Reactive Astrogliosis Response at
the Lesion Site Are Not Affected by NMII Ablation
Inflammation and astrogliosis are two anticipated responses to
local damage, critical for myelin debris clearance and repair
(Skripuletz et al., 2013). We investigated whether ablation of
NMIIB affected these responses by staining lesions at 14 dpi
with antibodies to Iba1, to identify mononuclear phagocytes
(macrophages/microglia), and GFAP, to identify astrocytes.
Results shown in Fig. 6 indicated that there were no significant
differences in the extent of inflammation and astrogliosis
between cKO and control animals. Therefore, accelerated
repair in the cKO mice could not be attributed to these factors.
Oligodendrocytes Lacking NMIIB Are Present in
Remyelinated Areas
To investigate if accelerated myelin repair in cKO mice was
directly mediated by Plp1 cells lacking NMIIB, we generated
double transgenic PlpCre/ESR1:Rosa26-mT/mG mice carrying
FIGURE 2: Morphological analysis of uninjured corpus callosum in control and cKO brains. (A): Electron micrographs from uninjured cor-
pus callosum of control and cKO of 16-week-old mice reveal normal myelin morphology, periodicity (inset), and g-ratio (B). Values in
graph were obtained from three animals per genotype, for a total of 183 axons measured. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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FIGURE 4: Comparison of lesion progression in control and cKO mice. (A): Fluoromyelin and Olig2 staining of lesion at 7, 14, and 28
days post lysolecithin injection and corresponding lesion volume quantitation (B), showing that the maximal extent of demyelination
measured at 7 dpi and lesion resolution at 28 dpi are comparable between the control and cKO mice. Lesion volume only differed signif-
icantly at 14 dpi, the peak of remyelination (Mann Whitney t-test **P<0.01). Results were obtained from five to nine animals per geno-
type, per time point, three different fields per animal.
FIGURE 3: Lesion volume is reduced in mice with conditional ablation of NMIIB. (A): Caudal–rostral (left to right) projection of 30 mm
brain sections stained with FluoroMyelin (green) and CC1 antibody (blue) showing a significantly smaller lesion in cKO animals compared
with controls at 14 dpi. (B): Images of maximum lesion area at 14 dpi showing an increased number of CC11 OL (blue) in cKO animals
compared with controls. Scale bars 100 mm. (C–E): Quantitation of average lesion volume, Olig21 and CC11 cells at 14 dpi (Mann Whit-
ney t-test **P<0.01). Results were obtained from five to nine animals per genotype, per time point, three different fields per animal.
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FIGURE 5: Accelerated remyelination occurs in mice with conditional ablation of NMIIB. (A, B): Light microscopy of epoxy sections
stained with toluidine blue showing representative pathology from 14 dpi lysolecithin lesions in control and cKO animals. Normal
appearing white matter (NAWM) is also shown. (B): Details of areas boxed in panels (A). The lesion center contains reactive astrocytes
(As), lipid-filled mononuclear monocytes (M), and demyelinated axons; but is smaller in cKO animals. The lesion border in cKO contains
many axons surrounded by abnormally thin myelin, a characteristic of remyelinated axons (arrowheads). Many cells with morphology
consistent with oligodendrocyte lineage (OL) are also observed in the cKO lesion. A remyelinated axon in transverse section (*) is also
shown. (C): Examples of normal myelinated axons (top) taken from NAWM area and remyelinated axons (bottom) taken from lesion bor-
der area are shown (left panels toluidine blue stain and right panels EM). (D–G): Examples of pathology are illustrated by EM of serial
grids from control (D) and cKO (E–G) lesions. (D): A macrophage (M) is seen adjacent to a demyelinated axon (arrowheads) at 7 dpi. (E):
Details of multiple remyelinated axons (*) at 7 dpi. (F): A lipid-filled macrophage (M) at 14 dpi. (G): An oligodendroglial cell (OL) is seen
at the border of a lesion containing multiple remyelinated axons (*) at 14 dpi.
TABLE 1: Comparison of Lysolecithin Lesions at 7 dpi
Control cKO
Total DAPI1 cells/area 10.246 0.38 3 103 mm2 11.176 0.24 3 103 mm2
% Ki671 cells 1.316 0.73% 1.786 0.99%
% Caspase 31cells 0.286 0.05% 0.296 0.06%
% Olig21 cells 9.036 0.05% 8.516 0.75%
NF staining (AU)a 61.786 6.13% 61.976 5.16%
Data in table represents mean6 SEM calculated from three to four mice per genotype (three fields per mice).
NF: neurofilament.
aAU: arbitrary units for mean gray value.
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wild-type (Control) or floxed (cKO) NMIIB alleles. Focal
demyelination with lysolecithin was induced at 12 weeks as
before and lesion resolution was examined at 28 dpi. The
results shown in Fig. 7 demonstrate that EGFP1 myelinating
OL were more frequently found within the remyelinated area
of cKO mice (Fig. 7A). Thus, the percentage of the remyeli-
nated area covered by EGFP1 cells (Fig. 7B) was signifi-
cantly larger in cKO mice than controls (4.3%6 2.6 cKO vs.
1.06%6 1.1 control, mean6 SD; P5 0.0004, t-test).
Double staining of the remyelinated area in the double
transgenic cKO mice showed that although NG21 progenitors
predominate in the lesion and lesion border, non-myelinating
EGFP1,Olig21, NG22 cells are also present (Fig. 7C). These
cells might represent adult pre-myelinating OL (Chang et al.,
2012; Trapp et al., 1997) or surviving demyelinated OL which
are known to have a restricted capacity for remyelination in
the lysolecithin model (Crang et al., 1998). Importantly, our
data indicate that their contribution to myelin repair can be
potentiated by NMII ablation.
To test the relevance of our findings to inflammatory-
mediated demyelination, we induced focal demyelination by
stereotactic injection of pro-inflammatory cytokines (Argaw
et al., 2006) in the corpus callosum of control and cKO mice
subclinically immunized with MOG. This approach is a
modification of cortical EAE (Merkler et al., 2006; Pluchino
et al., 2008), a model that mimics human cortical MS lesions
and allows the study of the pathogenetic events and remyeli-
nation in a temporally well-defined manner. Preliminary
results obtained with this model indicate that, similar to our
findings with lysolecithin-mediated demyelination, average
FIGURE 6: Axonal preservation, progenitor recruitment, inflammation, and reactive astrogliosis are not affected by NMIIB conditional
ablation. (A): Sections from control and cKO corpus callosum (14 dpi) immunostained with neurofilament (NF), NG2, Iba1, and GFAP
antibodies to evaluate, respectively: axonal preservation, the presence of progenitors, and the extent of inflammation and reactive
astrogliosis at the lesion center. (B): Quantitation of fluorescence intensity by normalized mean gray value shows that all parameters
were comparable between cKO and control mice, and the small differences in fluorescence intensity were not statistically significant.
Data collected from 9 to 10 animals per genotype, three fields per animal. Scale bars 50 mm.
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lesion volume at 15 days post-cytokine injection (the time of
lesion resolution in this model) is smaller in cKO mice com-
pared with controls and that GFP1 oligodendrocytes lacking
NMIIB contribute to myelin repair (Supp. Info. Fig. S1).
Collectively, these data confirm our previous findings
that NMII is a negative regulator of OL development (Wang
et al., 2008, 2012); and that its absence/inhibition not only
potentiates OL differentiation and de novo myelin formation,
but it is also relevant to adult myelin repair.
Discussion
This study demonstrate that downregulation of NMIIB in
OL potentiates differentiation and myelin formation in vivo,
and provides the proof of concept of its relevance to myelin
repair. Here, we have performed studies in the context of a
toxic insult to myelin, namely lysolecithin-induced demyelin-
ation, in the adult mouse corpus callosum. This model per-
mits detailed experimental analysis of the timing and extent
of remyelination, a question central to multiple sclerosis
(Frohman et al., 2006). By specifically targeting oligodendro-
cytes using the inducible Cre/lox system driven by the Plp
promoter, we have been able to demonstrate that mice lacking
NMIIB before receiving a demyelinating lesion, which ini-
tially exhibits the same size and a similar inflammatory/reac-
tive cell response as those of controls, show accelerated
remyelination, and more importantly that Plp-expressing oli-
godendrocyte-lineage cells contribute to this repair. This
result is consistent with our hypothesis that NMIIB acts as
negative regulator of OL differentiation (Wang et al., 2008,
2012).
Based on our data, enhanced remyelination in the
absence of NMII ablation does not result from differences in
proliferation or recruitment of progenitors, nor in enhanced
survival as evidenced by Ki67, NG2, and caspase staining and
FIGURE 7: Myelinating oligodendrocytes lacking NMIIB are present in remyelinated areas. (A): Representative images from 28 dpi
lysolecithin lesions from transgenic PlpCre/ESR1:Rosa26-mT/mG mice carrying wild-type (Control) or floxed (cKO) NMIIB alleles. EGFP1
myelinating cells within the remyelinated MBP1 area (blue) were more frequently found in cKO animals. Scale bar 50 mm. (B): Quantita-
tion of percentage area remyelinated by EGFP1 OLs in control and cKO animals (Mann Whitney t-test ***P<0.001). Data collected from
three animals per genotype, three to five fields per animal. Scale bars 50 mm. (C): Examples of NG22 (top panel); Olig21 (bottom panel)
EGFP-expressing OL (arrowheads) found in the lesion border of remyelinated areas in double transgenic cKO mice.
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by the presence of similar numbers of Olig21 cells in both
cKO and control lesions. Although we cannot entirely rule
out the contribution of non-cell autonomous effects to
enhanced remyelination in the cKO brain, we found no evi-
dence at the histological level of changes in the extent of
inflammation, astrogliosis and/or axonal damage between
cKO and control mice. The only significant differences in the
cKO mice were the presence of a smaller lesion area and an
increase in the number of CC11 mature OL at 14 dpi.
These changes are consistent with enhanced myelin formation
by OL in the absence of NMIIB. In support of this interpre-
tation, we and others have found that inhibition of NMII
activity in OL promotes branching, plasma membrane con-
densation and differentiation (Kippert et al., 2007; Wang
et al., 2012), effects that might translate into enhanced myeli-
nogenic potential of individual cells (Chong et al., 2012).
Previous studies have established the participation of
SVZ-derived progenitors (Nait-Oumesmar et al., 1999), as
well as of NG21 progenitors (Watanabe et al., 2002), to
CNS remyelination after lysolecithin. Despite the presence of
large pools of heterogeneous progenitors (Gensert and Gold-
man, 2001) and the existence of recent studies demonstrating
the expression of Plp in a small subpopulation of NG21 cells
in adult brain (Mallon et al., 2002), we observed a significant
increase in remyelination by a relatively low number of
EGFP1, Olig21, NG22 oligodendrocytes lacking NMIIB.
Thus, using the Rosa26 (mT/mG) reporter we have demon-
strated the direct involvement of adult Plp-expressing oligo-
dendrocytes to remyelination. The contribution of this cell
population to myelin repair, which are most likely recruited
from local sites of myelin injury, has long been debated
[reviewed in Bruce et al. (2010)]. Classic studies using trans-
plantation of postmitotic, radiation-resistant cells isolated
from adult brain into demyelinated lesions, demonstrated the
existence of a heterogenous population of adult oligodendro-
cytes some of which are capable to form myelin (Crang et al.,
1998). Similarly the presence of pre-myelinating oligodendro-
cyte that can remyelinate axons has also been described
(Ludwin, 1979).
As MS targets white matter throughout the CNS (Froh-
man et al., 2006), affecting regions such as the optic nerve
and spinal cord, which are not readily accessible to SVZ-
derived progenitors, these disease foci might benefit from
strategies that promote remyelination by resident OL. Of
note the presence of Plp1, non-myelinating oligodendrocytes,
has been reported in adult human and rodent brain as well as
in chronic demyelinating lesion in MS (Chang et al., 2002,
2012; Wolswijk, 2000). These cells are likely to reflect a
diverse population, which includes mature oligodendrocytes
that have lost their myelin and non-myelinating pre-oligoden-
drocytes. Although the former population is known to have a
very restricted remyelination potential (Crang et al., 1998),
pre-oligodendrocytes might be stimulated to produce myelin
(Ludwin, 1979). Our findings highlight the relevance of this
population as potential therapeutic targets for myelin repair.
Previous studies have shown that inhibition of ROCK,
a known regulator of NMII activity (Kimura et al., 1996),
ameliorates disease progression in mice with EAE (Hou et al.,
2012; Huang et al., 2011; Yu et al., 2010). Although the con-
clusions of these studies implicate modulation of both the
inflammatory response and blood–brain barrier permeability
as the main cause underlying these beneficial effects, it is not
implausible that enhanced differentiation (Kippert et al.,
2007; Wang et al., 2012) and OL-mediated remyelination
(this work) could also account for improved clinical recovery.
Failure of remyelination may result in axonal atrophy
and neurodegeneration, changes that are largely responsible
for the progressive functional decline in patients with
chronic demyelination. Promotion of endogenous repair
may offer the potential to prevent long-lasting damage and
clinical disability. Our initial studies using a model of demye-
lination which mimics some aspects of MS pathology (Supp.
Info. Fig. S1) suggest that similar to our findings in the lyso-
lecithin model, repair of demyelinated lesions following
inflammatory-mediated damage is also accelerated in the
absence of NMII.
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